Vas Narasimhan

Reimagining medicine as CEO of @Novartis

[Vas Narasimhan @VasNarasimhan]

On the latest episode of The @DM_Rubenstein Show: Peer-to-Peer Conversations, I had the chance to speak with David about my career and leadership journey and all I’ve learned along the way.

I hope you’ll watch the episode here: https://t.co/9WR2LheJRA

[Vas Narasimhan @VasNarasimhan]

Great to talk with @JimCramer yesterday morning about what @Novartis’ renewed strategy has meant for our business performance and the strength of our pipeline of innovative medicines. #JPM24

[Vas Narasimhan @VasNarasimhan]

Novartis is entering its new era as a focused medicines company from a position of strength.

Today, I’m proud to share our very strong results for Q3.

Read more from @Novartis here: https://t.co/ITofSd6kl7

[Novartis @Novartis]

Novartis delivered a very strong quarter, with double-digit sales and core operating income growth leading to a further upgrade to 2023 guidance.

#NovartisNews $NVS $NOVN #NVSQ323

[Vas Narasimhan @VasNarasimhan]

Today’s announcement is another promising step forward on our journey to reimagine medicine for and with patients around the world.

[Novartis News @NovartisNews]

Novartis announces initial Ph 3 trial results of complement inhibitor in rare kidney disease IgAN #NovartisNews

[Novartis US @NovartisUS]

Our Beacon of Hope summer fellowship students met CEO @VasNarasimhan and had the chance to ask him questions and share their experiences at Novartis labs. We look forward to continuing to support students from Historically Black Medical Schools and break down #DEI barriers.

[Vas Narasimhan @VasNarasimhan]

These trial results bring us one step closer to a potential first-in-class treatment for patients living with CSU.

Thank you to all those involved in this study.

[Novartis News @NovartisNews]

Novartis announces REMIX Phase III studies met their primary endpoint in chronic spontaneous urticaria – an unpredictable and debilitating immunological condition. #NovartisNews

[Novartis News @NovartisNews]

Novartis delivers strong sales growth, robust margin expansion and raises guidance. Announces USD 15 billion share buyback and Board endorses Sandoz spin-off.

#NovartisNews $NVS $NOVN #NVSQ223

[Vas Narasimhan @VasNarasimhan]

IgA nephropathy is a devastating disease, mostly affecting young adults, that could lead to dialysis or kidney transplantation. We’re excited by the opportunity to address this healthcare challenge, with the potential to bring additional, much-needed treatment options to patients.

[Novartis News @NovartisNews]

For #Media & #Investors:

Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront.

[Vas Narasimhan @VasNarasimhan]

So much of the power of science is realized through community—through the ways we share research, come together around tough scientific challenges, and work together to tackle diseases like cancers. 

Proud to have joined our @Novartis teams at ASCO, where we shared strong and exciting data for our trial in early breast cancer. 

Through scientific advancements like this, through new technologies like radioligand therapy, and through other efforts to reimagine medicine, Novartis remains committed to beating cancer.

[Vas Narasimhan @VasNarasimhan]

It was great to sit down with the team at @YahooFinance to talk about some of the exciting news in oncology at @Novartis and what our renewed strategy means for our pipeline of innovative medicines.

Thanks for having me, @juleshyman @AnjKhem @thebradsmith.

[Yahoo Finance @YahooFinance]

���Over the past 10 years… we’ve completely refocused Novartis from being a broad conglomerate," @Novartis CEO @VasNarasimhan says. "We had seven divisions… now we’re just focusing on high-end innovative medicines..."

[Vas Narasimhan @VasNarasimhan]

I want to encourage @Harvard alumni in my network to vote in the #Harvard elections before they close this week. I couldn’t be prouder my wife Srishti Gupta Narasimhan has been nominated for the Board of Overseers—a testament to her leadership and commitment to education.

Voting closes May 16th. Find your ballot by searching your inbox for an email from [email protected].

[Vas Narasimhan @VasNarasimhan]

I spent part of my early career in malaria clinics across Africa and continue to be passionate about creating a malaria-free world.

As we marked #WorldMalariaDay this week, I wanted to share the history of this ancient scourge and perspectives for the way forward: https://t.co/FZQZ3atoMx

[Vas Narasimhan @VasNarasimhan]

Highlighted by a positive Phase 3 readout in early breast cancer, our pipeline momentum gives us confidence in our growth outlook. More on our Q1 results and the strong growth Novartis delivered to start 2023: https://t.co/fKxsy2D39t

[Vas Narasimhan @VasNarasimhan]

With the strong Q1 results we shared today, I’m extremely proud of how Novartis has started 2023. Our strong start to the year and confidence in our growth drivers allow us to raise our full-year guidance.

[Novartis News @NovartisNews]

Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance.

#NovartisNews $NVS $NOVN #NVSQ123

[Vas Narasimhan @VasNarasimhan]

The heart of our company is our science. Today’s news builds on our longstanding commitment to improving and extending the lives of breast cancer patients.

I couldn’t be prouder of our teams working on this medicine.

[Novartis News @NovartisNews]

Novartis announces topline data from a Phase III study of a CDK4/6 inhibitor in a broad population of people diagnosed with stage II and III HR+/HER2- early #BreastCancer #NovartisNews

[Vas Narasimhan @VasNarasimhan]

About to go live #HBRat100. Looking forward to an energizing conversation about the future of business and @Novartis's important role in the next generation of health. Thanks for having me, @HarvardBiz.

[Vas Narasimhan @VasNarasimhan]

Congratulations again @KTRBRS, it was an honor to join you.

[Vas Narasimhan @VasNarasimhan]

I was thrilled to speak about the future of medicine at #BioAsia23 & how the industry has increased its presence in Hyderabad over the years. @Novartis was one of the first to open a site—what is now one of our largest corporate centers at the heart of our global efforts.

[Vas Narasimhan @VasNarasimhan]

Thanks to the incredible @ShereenBhan for an energizing conversation.

[Vas Narasimhan @VasNarasimhan]

My top takeaways from @cnbctv18news:
• India could become the next biopharma hub, but must create the right conditions in the innovation ecosystem
• Novartis is a fully focused medicines company with a renewed strategy
• We are committed to India, a world-class talent hub

[CNBC-TV18 @CNBCTV18News]

‘World is watching to see if India can transition from being a generics player to a partner to innovators’ Vas Narasimhan, global CEO @Novartis in conversation with @ShereenBhan #healthcare #pharma